Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 8
2002 6
2003 7
2004 16
2005 28
2006 59
2007 77
2008 93
2009 135
2010 134
2011 133
2012 156
2013 180
2014 170
2015 137
2016 111
2017 109
2018 81
2019 73
2020 54
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

1,559 results
Results by year
Filters applied: . Clear all
Page 1
Temsirolimus.
Schulze M, Stock C, Zaccagnini M, Teber D, Rassweiler JJ. Schulze M, et al. Recent Results Cancer Res. 2014;201:393-403. doi: 10.1007/978-3-642-54490-3_24. Recent Results Cancer Res. 2014. PMID: 24756806 Review.
In this study, median overall survival was 10.9 versus 7.3 months and objective response rates were 8.6% in temsirolimus recipients versus 4.8% IFN-alpha recipient group. Temsirolimus monotherapy recipients experienced significantly fewer grade 3 or 4 adverse events …
In this study, median overall survival was 10.9 versus 7.3 months and objective response rates were 8.6% in temsirolimus recipients v …
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. ...Ibrutinib was better tolerated than temsirolimus
BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown s …
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
Of the remaining 35 patients, 18 were randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-dinutuximab. Median follow-up was 126 years (IQR 068-161) among all eligible participants. Of the 18 patients assigned to irinotecan-temozolomi …
Of the remaining 35 patients, 18 were randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-din …
Temsirolimus metabolic pathways revisited.
Shokati T, Hartmann M, Davari B, Klawitter J, Klawitter J, Christians U. Shokati T, et al. Xenobiotica. 2020 Jun;50(6):640-653. doi: 10.1080/00498254.2019.1678793. Epub 2019 Oct 23. Xenobiotica. 2020. PMID: 31596164
Temsirolimus, a derivative of sirolimus, exhibits potent antitumor properties. ...Moreover, enzyme kinetic parameters of temsirolimus metabolite formation as well as the contribution of individual recombinant cytochrome P450 (CYP) enzymes to temsirolimus meta
Temsirolimus, a derivative of sirolimus, exhibits potent antitumor properties. ...Moreover, enzyme kinetic parameters of temsiroli
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Hudes G, et al. N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838. N Engl J Med. 2007. PMID: 17538086 Free article. Clinical Trial.
There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02). CONCLUSIONS: As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poo …
There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02). CONCLUSIONS: A …
Temsirolimus.
Ma WW, Jimeno A. Ma WW, et al. Drugs Today (Barc). 2007 Oct;43(10):659-69. doi: 10.1358/dot.2007.43.10.1148059. Drugs Today (Barc). 2007. PMID: 17987219 Review.
Temsirolimus (CCI-779), a small molecule inhibitor of mTOR protein, is a water-soluble synthetic rapamycin ester that has been developed in both oral and intravenous (i.v.) formulations. ...Patients receiving temsirolimus alone achieved longer survival than those re
Temsirolimus (CCI-779), a small molecule inhibitor of mTOR protein, is a water-soluble synthetic rapamycin ester that has been develo
Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Mascarenhas L, Chi YY, Hingorani P, Anderson JR, Lyden ER, Rodeberg DA, Indelicato DJ, Kao SC, Dasgupta R, Spunt SL, Meyer WH, Hawkins DS. Mascarenhas L, et al. J Clin Oncol. 2019 Nov 1;37(31):2866-2874. doi: 10.1200/JCO.19.00576. Epub 2019 Sep 12. J Clin Oncol. 2019. PMID: 31513481 Free PMC article. Clinical Trial.
Objective response rates were 28% (95% CI, 13.7% to 41.3%) and 47% (95% CI, 31.5% to 63.2%) for the bevacizumab and temsirolimus arms, respectively (P = .12) and, 28% of patients on bevacizumab and 11% on temsirolimus had progressive disease at 6 weeks. CONCLUSION: …
Objective response rates were 28% (95% CI, 13.7% to 41.3%) and 47% (95% CI, 31.5% to 63.2%) for the bevacizumab and temsirolimus arms …
Temsirolimus.
Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ. Stock C, et al. Recent Results Cancer Res. 2010;184:189-97. doi: 10.1007/978-3-642-01222-8_13. Recent Results Cancer Res. 2010. PMID: 20072839 Review.
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors. ...In this study, median overa
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently block
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.
Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY. Lee JB, et al. Cancer Res Treat. 2019 Oct;51(4):1578-1588. doi: 10.4143/crt.2018.671. Epub 2019 Apr 16. Cancer Res Treat. 2019. PMID: 30999721 Free PMC article.
PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. ...Temsirolimus was well-tolerated with manageable adverse events....
PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. …
Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
Chen Z, Yang H, Li Z, Xia Q, Nie Y. Chen Z, et al. Biochem Biophys Res Commun. 2019 Aug 27;516(3):726-732. doi: 10.1016/j.bbrc.2019.06.127. Epub 2019 Jun 26. Biochem Biophys Res Commun. 2019. PMID: 31253398
Temsirolimus potently inhibits retinal angiogenesis via targeting biological functions of retinal endothelial cells. ...In line with in vitro data, we further demonstrate the inhibitory effects of temsirolimus on retinoblastoma and angiogenesis in in vivo xenograft
Temsirolimus potently inhibits retinal angiogenesis via targeting biological functions of retinal endothelial cells. ...In line with
1,559 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page